MedPath

The investigation about bone metabolism and sarcopenia among chronic hepatitis C patients and the impacts of DAAs combination therapy.

Not Applicable
Conditions
Chronic hepatitis C
Registration Number
JPRN-UMIN000027717
Lead Sponsor
ippon Medical School Chiba Hokusoh Hospital
Brief Summary

The prevalence of sarcopenia in the cirrhotic patients was significantly higher than that in the noncirrhotic patients. Sarcopenia was diagnosed in 27.5% of the 160 patients with vitamin D deficiency, and 4.5% of the 44 patients without vitamin D deficiency. On multivariate analysis, advanced age, low bodymass index and low serum 25(OH)D3 level were significant independent factors associated with sarcopenia. Serum 25(OH)D3 was positively correlated with grip strength and skeletal muscle mass index.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
204
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patient who already takes some medicine affecting bone density 2. Patient who is nursing or pregnant 3. Patient with uncontrolled heart failure 4. Patient with uncontrolled hypertension or diabetes 5. Patient with chronic renal failure 6. Patient with decompensated liver cirrhosis 7. Patient with other liver diseases, including autoimmune hepatitis, primary biliary cirrhosis and alcoholic hepatitis 8. Patient with positive result for hepatitis B surface antigen and antibody to human immunodeficiency virus type-1 9. Patient Judged by investigators not to be appropriate for inclusion in this study

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath